This site is intended for health professionals only
Sunday 21 April 2019
Share |

Topic: Nephrology

April 19, 2018
Three studies shed light on cancer evolution and could lead to tests that give more accurate prognoses and personalised treatment

Kidney cancer follows distinct evolutionary paths, scientists have discovered. Their findings will enable them to detect whether a tumour will be aggressive, and also reveal that the first seeds of kidney cancer are sown as early as childhood.

 

February 27, 2018
ACH-4471 is a first-in-class, oral inhibitor of complement factor D

Achillion Pharmaceuticals has announced that the European Medicines Agency  Committee for Orphan Medicinal Products has issued a positive opinion on ACH-4471 for orphan status in the EU for the treatment of C3 glomerulopathy (C3G).

 

February 12, 2018
Tivozanib was licensed by the European Commission in August 2017 and is an oral, once-daily, potent selective vascular endothelial growth factor receptor tyrosine kinase inhibitor

EUSA Pharma has announced that the National Institute for Health and Care Excellence (NICE) has published a Final Appraisal Determination (FAD) recommending tivozanib as a first-line treatment option for advanced renal cell carcinoma (aRCC) in line with its licensed indication.

 

December 12, 2017
Renal cell carcinoma is the most common type of kidney cancer in adults, with 80% of kidney cancer patients in the UK diagnosed with this type

Eisai Europe Limited has announced that the National Institute for Health and Care Excellence (NICE) has given a positive recommendation for the use of Kisplyx® (lenvatinib) in combination with everolimus for the treatment of adults with advanced renal cell carcinoma (RCC) following one prior vascular endothelial growth factor (VEGF)-targeted therapy, if their Eastern Cooperative Oncology Group (ECOG) performance status score is 0 or 1, and the company provides lenvatinib with the discount agreed in the patient access scheme.1

November 9, 2017
Tolvaptan reduced the rate of decline of kidney function by 35% over a 12-month period, compared to placebo, in patients with autosomal dominant polycystic kidney disease

Otsuka has announced detailed results from the Phase III REPRISE trial of tolvaptan in patients with autosomal dominant polycystic kidney disease (ADPKD).
 

July 13, 2017
NICE endorses prescribing across the NHS of Ipsen’s tablet cabozantinib, offering a new therapy option to help battle cancer resistance in advanced renal cell carcinoma in adults (after VEGF-targeted therapy)

The UK affiliate of Ipsen has announced that eligible patients with advanced kidney cancer could now benefit from treatment with Ipsen’s innovative therapy Cabometyx® (cabozantinib) via the NHS in England and Wales, following recommendation for use by NICE in their Final Appraisal Determination (FAD).

June 29, 2017
If approved, it will be indicated for the first-line treatment of adult patients with advanced renal cell carcinoma and for adult patients who are VEGFR and mTOR pathway inhibitor-naïve following disease progression after one prior treatment with cytokine therapy

EUSA Pharma has announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending marketing authorisation of Fotivda (tivozanib) for the management of adult patients with advanced renal cell carcinoma (RCC) in the European Union plus Norway and Iceland.

 

January 19, 2016
Swedish Orphan Biovitrum AB (publ) (Sobi) announced that the European Patent Office (EPO) has decided to grant a European patent for the Orfadin® (nitisinone) oral suspension formulation

Swedish Orphan Biovitrum AB (publ) (Sobi) announced that the European Patent Office (EPO) has decided to grant a European patent for the Orfadin® (nitisinone) oral suspension formulation, which was approved by the European Commission for the treatment of Hereditary Tyrosinaemia type-1 (HT-1) in 2015. HT-1 is a rare genetic disease that affects infants and children. It is progressive and may result in liver and kidney complications and can be fatal if untreated.

 

January 11, 2016
JINARC® (tolvaptan) is accepted for use in Scotland for the treatment of autosomal dominant polycystic kidney disease (ADPKD)

May 6, 2015
Swedish Orphan Biovitrum AB (publ) (Sobi) announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion for the oral suspension formulation and the 20mg capsule of Orfadin (nitisinone) for the treatment of hereditary tyrosinaemia type-1 (HT-1). HT-1 is a rare genetic disease that affects infants and children; it is progressive in nature, may result in liver and kidney failure and can be fatal if untreated.

Swedish Orphan Biovitrum AB (publ) (Sobi) announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion for the oral suspension formulation and the 20mg capsule of Orfadin (nitisinone) for the treatment of hereditary tyrosinaemia type-1 (HT-1). HT-1 is a rare genetic disease that affects infants and children; it is progressive in nature, may result in liver and kidney failure and can be fatal if untreated.  

March 19, 2015
The International Society of Nephrology (ISN) will present the findings of a new global study on Acute Kidney Injury (AKI), seen by experts as a key step forward in their efforts to eliminate preventable deaths from the condition by 2025 (0by25).

The International Society of Nephrology (ISN) will present the findings of a new global study on Acute Kidney Injury (AKI), seen by experts as a key step forward in their efforts to eliminate preventable deaths from the condition by 2025 (0by25).

AKI is a worldwide problem, killing affected patients who have no means to reach appropriate therapy in developing countries, and who could be saved with as little as $150.

January 30, 2015
A report has been published by the European ADPKD Forum (EAF), an international, multidisciplinary panel of experts from the fields of nephrology, hepatology and genetics, as well as patient group representatives, dedicated to improving the health and quality of life of people with autosomal dominant polycystic kidney disease (ADPKD) – a chronic, progressive, inherited disease in which fluid-filled cysts grow in the kidneys and liver.

A report has been published by the European ADPKD Forum (EAF), an international, multidisciplinary panel of experts from the fields of nephrology, hepatology and genetics, as well as patient group representatives, dedicated to improving the health and quality of life of people with autosomal dominant polycystic kidney disease (ADPKD) – a chronic, progressive, inherited disease in which fluid-filled cysts grow in the kidneys and liver. (1)
 

January 20, 2015
Moderate chronic kidney disease affects up to 40% of all people with type 2 diabetes in the UK, which is approximately one million people (1,2). Type 2 diabetes costs the NHS a total of £21.8 billion in 2010/2011, with the complications of chronic kidney disease accounting for an estimated £753.8 million. These figures are predicted to rise to £35.6 billion for type 2 diabetes and £1.3 billion for kidney disease in people with type 2 diabetes by 2035/36 (3). The licence extension for Victoza® (liraglutide) increases clinicians’ prescribing options to help patients with both conditions achieve glucose control.
  • Moderate chronic kidney disease affects up to 40% of all people with type 2 diabetes in the UK, which is approximately one million people (1,2).
  • Type 2 diabetes costs the NHS a total of £21.8 billion in 2010/2011, with the complications of chronic kidney disease accounting for an estimated £753.8 million. These figures are predicted to rise to £35.6 billion for type 2 diabetes and £1.3 billion for kidney disease in people with type 2 diabetes by 2035/36 (3).
November 24, 2014
The Committee for Medicinal Products for Human Use (CHMP) today issued a positive opinion for the use of Victoza® (liraglutide) in adults with type 2 diabetes and moderate renal impairment. Once the European Commission approves the label expansion, physicians in the European Union will be able to prescribe Victoza®, the once-daily human glucagon-like peptide-1 (GLP-1) analogue, to adults with type 2 diabetes and moderate renal impairment without dose adjustments.

The Committee for Medicinal Products for Human Use (CHMP) today issued a positive opinion for the use of Victoza® (liraglutide) in adults with type 2 diabetes and moderate renal impairment. Once the European Commission approves the label expansion, physicians in the European Union will be able to prescribe Victoza®, the once-daily human glucagon-like peptide-1 (GLP-1) analogue, to adults with type 2 diabetes and moderate renal impairment without dose adjustments.

 

August 27, 2014
A previously unknown role played by the hormone FGF23 has been discovered in a project funded by the Austrian Science Fund FWF.

A previously unknown role played by the hormone FGF23 has been discovered in a project funded by the Austrian Science Fund FWF.

June 2, 2014
The European ADPKD Forum (EAF) has been created, which is a new multidisciplinary group of leading medical and patient group experts dedicated to improving the health and quality of life of people with autosomal dominant polycystic kidney disease (ADPKD).

The European ADPKD Forum (EAF) has been created, which is a new multidisciplinary group of leading medical and patient group experts dedicated to improving the health and quality of  life of people with autosomal dominant polycystic kidney disease (ADPKD).

The EAF initiative, co-chaired by Tess Harris, President of PKD International and Dr Richard Sandford, Consultant Clinical Geneticist at Addenbrooke’s Hospital, Cambridge aims to:

June 7, 2013
The article discusses the importance of pain assessment to identify the cause and impact of pain and pharmacological pain management strategies in the context of chronic kidney disease

teaser

April 15, 2013
Following the submission of the New Drug Application (NDA) for PA21, the US Food and Drug Administration (FDA) has announced that it has accepted the filing and assigned a PDUFA (Prescription Drug User Fee Act) target action date of 1 December 2013 to complete its review.

teaser

January 15, 2013
Physicians who prescribe a combination of two antihypertensive drugs to their patients may want to be extra vigilant if non-steroidal anti-inflammatory drugs (NSAIDs) are added to a patient

teaser

December 4, 2012
Baxter International has entered into a definitive agreement to acquire Gambro, a privately held dialysis product company based in Lund, Sweden, for total consideration of 26.5 billion SEK, or approximately $4 billion US at current exchange rates.

teaser

November 28, 2012
Mitsubishi Pharma Europe has announced the UK launch of Exembol

teaser

November 5, 2012
Novartis received approval from the European Commission (EC) for Votubia

teaser

September 21, 2012
The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion for Votubia

teaser

August 22, 2012
W. L. Gore & Associates has received CE Mark for the Gore Hybrid Vascular Graft, which is designed to expand treatment options for outflow by maximizing the number of access sites available.

teaser

You are leaving www.nursinginpractice.com

You are currently leaving the Nursing in Practice site. Are you sure you want to proceed?

Close

Respect for nurses: Sign up to our e-petition TODAY

The Nursing in Practice Respect campaign is now live! Over the coming months, we're set to highlight the vital contribution and efforts of primary care and community care nurses throughout the UK.

As part of our campaign, Nursing in Practice is looking to call on parliament to set up a debate to celebrate the vital work that you do.


GET INVOLVED: SIGN OUR E-PETITION

Close

Calling all primary care nurses! 'Like' our Nursing in Practice Facebook page to enter our free draw to win a £25 M&S voucher




http://www.facebook.com/NursinginPracticeMagazine